Selective targeting of IL2Rß? combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC.
Gadwa J, Amann M, Bickett TE, Knitz MW, Darragh LB, Piper M, Van Court B, Bukkapatnam S, Pham TT, Wang XJ, Saviola AJ, Deak LC, Umaña P, Klein C, D'Alessandro A, Karam SD. Selective targeting of IL2Rß? combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC. Cell Rep Med. 2023 08 15; 4(8):101150.